68Ga-YQ-CC05 PET-CT scan for finding thyroid, lung and stomach tumors
Tests a new scan tracer in adults with thyroid, lung or stomach cancer.
Plain-language title generated from the registry record
Registry title: 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
Key facts
- Where
- Nanjing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07914764, who can take part
Where in China
- Nanjing First HospitalNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Trial code
- NCT07914764
- Record updated
- 4 November 2026
- Original description
Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.Read full original descriptionShow less
Clinical Application Research of 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.
Inclusion: Volunteer to participate in the trial, with the patient or their legal guardian signing the informed consent form; Volunteers are not limited by gender, and the age range is from 18 to 75 years old, inclusive; Other imaging examination methods (CT, MRI, etc.) reveal tumor occupying lesions; Tumor patients who can obtain the final pathological results; Kidney: GFR > 50 ml/min, ERPF > 280 ml/min, platelet count (PLT) > 75,000/μL, white blood cell (WBC) > 3,000/μL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the normal value.
Exclusion: Those who are currently participating in other clinical drug studies, or have previously participated in any clinical drug studies (excluding vitamins and minerals); Expected survival duration less than half a year; chemotherapy within 6 months; Having severe acute concomitant diseases or severe treatment-resistant mental disorders; Individuals with a history of allergy to similar drugs (drugs with similar chemical or biological components to CCK2R), allergic constitution, or current allergic diseases; Other uncontrollable clinical issues (such as HIV, hepatitis C virus infection, active hepatitis B, or other severe chronic infections, as well as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases); Red blood cells (RBC) count less than 4×10\^12, white blood cells (WBC) count less than 3×10\^9, hemoglobin level less than 110g/L, and platelet count (PLT) less than 75,000×10\^9; Obvious abnormalities in liver and kidney function, with GFR less than 50 ml/min; Tumor burden greater than 50%, or significant spinal cord compression; Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy test result); Patients who are physically unfit for radiological examinations; Other situations where the researcher deems it inappropriate for the participant to participate in the trial.